Cytosorbents CFO Peter Mariani buys $27,974 in stock Investing.com Published 12/13/2024, 08:01 AM
These open market purchases reflect Mariani's ongoing investment in the company, increasing his total holdings to 381,363 shares. With analyst price targets ranging from $1 to $10, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro's detailed research reports. With analyst price targets ranging from $1 to $10, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro's detailed research reports. These open market purchases reflect Mariani's ongoing investment in the company, increasing his total holdings to 381,363 shares.
In other recent news, CytoSorbents Corporation has announced the terms of an upcoming Rights Offering. The medical technology company aims to raise between $3.0 million and $5.0 million through the offering, which is expected to significantly improve liquidity. The proceeds are intended for general corporate purposes and to support operations through anticipated regulatory decisions on the company's DrugSorb-ATR marketing applications in 2025.
Simultaneously, CytoSorbents reported an 11% year-over-year increase in product sales for the third quarter of 2024, totaling $8.6 million. The company's flagship product, CytoSorb, has generated approximately $34 million in sales over the past year. Additionally, the company has made progress in its blood purification technology, particularly for critical care and cardiac surgery applications.
CytoSorbents is also preparing for the launch of DrugSorb ATR, a device aimed at reducing perioperative bleeding. The device has received two FDA breakthrough designations and is awaiting regulatory decisions from the FDA and Health Canada, expected in 2025. Amid these developments, CytoSorbents has managed to decrease its operating expenses by 25% and reduce its cash burn to $2.7 million.
Market Data 
Markets 
AI
